A comparison of 500 μg Roflumilast versus 10 mg Montelukast. A 24 weeks double-blind study in patients with Asthma. The PRIME-study

Study identifier:BY217/M2-017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected]

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

958

Study type

Interventional

Age

15 Years - 70 Years

Date

Study Start Date: 01 Oct 2003
Primary Completion Date: -
Study Completion Date: 01 Nov 2004

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Sponsors

Takeda

Collaborators

-

Inclusion and exclusion criteria